Evidence map›Paper›PMID 35058536›Full record

ArticleScientific reports2022

Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.

Sanji Ali, Jace Hendry, Duc Le, Prosanta K Mondal, Amer Sami, Haji Chalchal, Kamal Haider, Osama Ahmed, Ali El-Gayed, Philip Wright and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Sanji AliCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Jace HendryCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Duc LeCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Prosanta K MondalClinical Research Support Unit, University of Saskatchewan, Saskatoon, Canada.
Amer SamiCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Haji ChalchalCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Kamal HaiderCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Osama AhmedCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Ali El-GayedCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Philip WrightCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Mehrnoosh PaulsCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Kate JohnsonCollege of Medicine, University of Saskatchewan, Saskatoon, Canada.
Shahid AhmedCollege of Medicine, University of Saskatchewan, Saskatoon, Canada. shahid.ahmed@saskcancer.ca.
University of Saskatchewan · CASaskatchewan Cancer Agency · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adjuvant trastuzumab has been associated with superior survival in women with ≥ T1c or node-positive HER2-positive early-stage breast cancer; however, there is a lack of phase III trials in women with T1a/bN0 disease. Our study aimed to assess the outcomes of women with HER2-positive T1a/bN0 breast cancer who received adjuvant trastuzumab in Saskatchewan, Canada. We evaluated all women diagnosed with HER2-positive T1a/bN0 breast cancer in Saskatchewan between 2008 and 2017. We performed Cox proportional multivariable analysis to determine factors correlated with survival. In addition, inverse probability treatment weighting (IPTW) using propensity score was performed to assess benefit of adjuvant trastuzumab. Ninety-one eligible women with a median age of 61 years (range 30-89) were identified. Thirty-nine (43%) women received adjuvant trastuzumab. Women who received trastuzumab were younger and had a higher rate of T1b disease. Overall, 3% of women who received trastuzumab compared to 12% of women who did not receive trastuzumab developed breast cancer recurrence (p = 0.23). Five-year disease-free survival (DFS) of women who received adjuvant trastuzumab was 94.8% compared to 82.7% of women who did not receive trastuzumab (p = 0.22). Five-year overall survival was 100% of women who received trastuzumab compared to 90.4% of women who did not receive adjuvant trastuzumab (p = 0.038). In the multivariable analysis, grade III tumors were correlated with inferior DFS (hazard ratio [HR] 5.5, 95% CI [1.7-17.7]). The propensity score using the inverse probability of treatment weighting showed that lack of adjuvant trastuzumab was correlated inferior DFS, with an HR of 4 (95% CI 1.05-15.5). Women with HER2-positive T1a/bN0 breast cancer had overall low recurrence of breast cancer. However, the results of this exploratory analysis indicate that women who received adjuvant trastuzumab had better survival.

Indexed as

AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBreast NeoplasmsCanadaChemotherapy, AdjuvantCohort StudiesDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm Recurrence, LocalProportional Hazards ModelsTrastuzumabAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumab

Identifiers

PMID35058536
PMCPMC8776836
OpenAlexW4205404910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.